Age-related diseases, such as vision loss and cognitive decline, cause considerable economic, personal, and societal burden for individuals, their families, and broader communities.
By targeting age-related diseases, we believe that UNITY can treat these diseases, as well as contain healthcare costs and lessen the emotional and societal burden that comes with an aging population.
We are at the forefront of developing a new class of therapeutics that may address the root cause of many diseases of aging. By selectively eliminating or modulating senescent cells, we may restore aging or damaged tissues to a more functionally healthy state.
UBX1325 is the first senolytic approach intended to target senescent cells in diseased vasculature of the eye, while leaving healthy blood vessels intact. UBX1325 is currently in clinical development for diabetic macular edema.
Diabetic macular edema (DME) is the leading cause of blindness in adults with diabetes and a common complication of diabetic retinopathy. Current standard of care poses significant patient burden and many do not respond to these therapies. UBX1325 may be the first of a new class of neovascular treatments that provide a viable and much needed alternative to current treatment modalities.